Posts Tagged ‘comparative effectiveness’
July 10, 2024 — The headline is compelling. “Zepbound outperforms Ozempic and Wegovy in head-to-head weight loss study.” It certainly confirms the bias of a lot of people in the field. But is it true? Did tirzepatide (Zepbound) really beat semaglutide (Wegovy) in a head-to-head comparative study for obesity? In a word, no. Uncontrolled, Observational, and Inequivalent Dosing The […]
June 29, 2023 — After four exhilarating days of new possibilities for overcoming diabetes and obesity at ADA2023, we had to come back down to earth. The National Institute for Health and Clinical Excellence in the UK stepped up to this task right away. On Tuesday, NICE said nope to recommending tirzepatide use for type 2 diabetes in the […]
February 9, 2023 — Vitamin D is an illusory panacea. Popular fascination with this “sunshine vitamin” has drawn people to latch onto associations that it has with many conditions. But those associations, when tested, often turn out to be confounded. So does a new systematic review and meta-analysis of vitamin D in prediabetes tell a different story? Anastassios Pittas […]
July 15, 2015 — After sorting through a range of new drugs, surgeries, and medical devices for obesity care, the California Technology Assessment Forum (CTAF) voted unanimously yesterday that bariatric surgery offers a net health benefit for people with diabetes and a BMI between 30 and 35. A small group of advocates and experts commented and participated in this […]